Literature DB >> 22754662

Challenging pulmonary embolism - A new generation of oral anticoagulants.

Sérgio Barra1, Luís Paiva, Rui Providência.   

Abstract

Entities:  

Year:  2012        PMID： 22754662      PMCID： PMC3378187          DOI： 10.3978/j.issn.2072-1439.2012.05.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.

Authors:  E Oger
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

3.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

4.  Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Authors:  Harry R Büller; Alex S Gallus; Gerard Pillion; Martin H Prins; Gary E Raskob
Journal:  Lancet       Date:  2011-11-28       Impact factor: 79.321

5.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

6.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

7.  A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

Authors:  Harry R Buller; Anthonie W A Lensing; Martin H Prins; Giancarlo Agnelli; Alexander Cohen; Alexander S Gallus; Frank Misselwitz; Gary Raskob; Sebastian Schellong; Annelise Segers
Journal:  Blood       Date:  2008-07-11       Impact factor: 22.113

8.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Authors:  Sorrel E Wolowacz; Neil S Roskell; Jonathan M Plumb; Joseph A Caprini; Bengt I Eriksson
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

10.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.